India · Delayed Price · Currency is INR Zenith Drugs Statistics
Total Valuation
Zenith Drugs has a market cap or net worth of INR 722.82 million. The enterprise value is 1.27 billion.
| Market Cap | 722.82M |
| Enterprise Value | 1.27B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zenith Drugs has 17.15 million shares outstanding.
| Current Share Class | 17.15M |
| Shares Outstanding | 17.15M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.28% |
| Owned by Insiders (%) | 69.98% |
| Owned by Institutions (%) | n/a |
| Float | 5.15M |
Valuation Ratios
The trailing PE ratio is 18.33.
| PE Ratio | 18.33 |
| Forward PE | n/a |
| PS Ratio | 0.42 |
| PB Ratio | 0.99 |
| P/TBV Ratio | 1.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 8.15 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 32.24 |
| EV / Sales | 0.74 |
| EV / EBITDA | 8.10 |
| EV / EBIT | 13.13 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.75.
| Current Ratio | 1.37 |
| Quick Ratio | 0.78 |
| Debt / Equity | 0.75 |
| Debt / EBITDA | 3.51 |
| Debt / FCF | -65.55 |
| Interest Coverage | 1.90 |
Financial Efficiency
Return on equity (ROE) is 5.53% and return on invested capital (ROIC) is 5.53%.
| Return on Equity (ROE) | 5.53% |
| Return on Assets (ROA) | 3.47% |
| Return on Invested Capital (ROIC) | 5.53% |
| Return on Capital Employed (ROCE) | 10.36% |
| Weighted Average Cost of Capital (WACC) | 9.58% |
| Revenue Per Employee | 9.95M |
| Profits Per Employee | 229,221 |
| Employee Count | 172 |
| Asset Turnover | 0.98 |
| Inventory Turnover | 2.99 |
Taxes
In the past 12 months, Zenith Drugs has paid 14.45 million in taxes.
| Income Tax | 14.45M |
| Effective Tax Rate | 26.82% |
Stock Price Statistics
The stock price has decreased by -33.67% in the last 52 weeks. The beta is 1.36, so Zenith Drugs's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -33.67% |
| 50-Day Moving Average | 44.28 |
| 200-Day Moving Average | 45.43 |
| Relative Strength Index (RSI) | 46.07 |
| Average Volume (20 Days) | 20,680 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zenith Drugs had revenue of INR 1.71 billion and earned 39.43 million in profits. Earnings per share was 2.30.
| Revenue | 1.71B |
| Gross Profit | 484.69M |
| Operating Income | 96.80M |
| Pretax Income | 53.87M |
| Net Income | 39.43M |
| EBITDA | 156.86M |
| EBIT | 96.80M |
| Earnings Per Share (EPS) | 2.30 |
Balance Sheet
The company has 2.61 million in cash and 551.05 million in debt, with a net cash position of -548.44 million or -31.98 per share.
| Cash & Cash Equivalents | 2.61M |
| Total Debt | 551.05M |
| Net Cash | -548.44M |
| Net Cash Per Share | -31.98 |
| Equity (Book Value) | 733.22M |
| Book Value Per Share | 42.76 |
| Working Capital | 348.81M |
Cash Flow
In the last 12 months, operating cash flow was 88.69 million and capital expenditures -97.09 million, giving a free cash flow of -8.41 million.
| Operating Cash Flow | 88.69M |
| Capital Expenditures | -97.09M |
| Depreciation & Amortization | 60.05M |
| Net Borrowing | 48.35M |
| Free Cash Flow | -8.41M |
| FCF Per Share | -0.49 |
Margins
Gross margin is 28.31%, with operating and profit margins of 5.65% and 2.30%.
| Gross Margin | 28.31% |
| Operating Margin | 5.65% |
| Pretax Margin | 3.15% |
| Profit Margin | 2.30% |
| EBITDA Margin | 9.16% |
| EBIT Margin | 5.65% |
| FCF Margin | n/a |
Dividends & Yields
Zenith Drugs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 5.45% |
| FCF Yield | -1.16% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zenith Drugs has an Altman Z-Score of 2.07 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.07 |
| Piotroski F-Score | 5 |